-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A clinical trial of stereotactic ablation radiotherapy (SAbR) to control the progressive metastasis of solitary renal cell carcinoma
January 3, 2022—A new study from the Kidney Cancer Project (KCP) of the Harold C.
Metastatic kidney cancer is basically an incurable disease
With one exception, little is known about how resistance develops
"The current standard of treatment for metastatic progression is to change the systemic (drug) treatment," said Dr.
The KCP study found that when metastatic disease only progresses in a few sites, highly focused stereotactic ablation radiotherapy (SAbR) is an effective strategy to control metastatic disease, which is called low progression
This Canadian study involves multiple institutions across the country and is also a phase II trial.
Both studies used sequential SAbR treatment, but the disease progressed slowly.
These findings are based on the groundbreaking report of KCP researchers published in 2013 and retrospective studies by KCP and other researchers, which show the promise of SAbR treatment seldom progress
Local treatments, such as SAbR, are usually associated with minimal toxicity and are an attractive option to complement systemic treatments that are otherwise effective and well tolerated
Although both clinical trials involved a small number of patients, the consistent positive results show that this approach has its advantages
